

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/517,881		
		Filing Date	December 13, 2004		
		First Named Inventor	Robin Mark Bannister		
		Group Art Unit	Not yet assigned		
		Examiner Name	Not yet assigned		
Sheet	1	of	1	Attorney Docket Number	GJE-7147

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1					

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	F1	Office ³	Number ⁴	Kind Code ⁵ (if known)			

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/S.J./	R1	BENHAMOU, D. (REPRINT), Nefopam and Combined Analgesics, Annales Francaises D Anesthesie et de Reanimation (Dec. 2002) SP. ISS. SI, pages 9-14, Publisher: Editions Scientifiques Medicales Elsevier, Paris, France.	
/S.J./	R2	GHOSE, K. <i>et al.</i> , An Open Pilot Study of the Preventative Effect of Nefopam in Migraine Headaches, <i>Headache Quarterly</i> (1999) United States, vol. 10, no.3, pages 221-224.	
/S.J./	R3	LASSETER, K.C. <i>et al.</i> , Nefopam HCl Interaction Study With Eight Other Drugs, <i>Journal of International Medical Research</i> (1976), vol. 4, no. 3, pages 195-201.	
/S.J./	R4	Mimoz, O. <i>et al.</i> , Analgesic Efficiency and Safety of Nefopam vs. Propacetamol Following Hepatic Resection, <i>Anaesthesia</i> (June 2001), England, vol. 56, no. 6, pages 520-525.	
/S.J./	R5	MOFFAT A.C <i>et al.</i> , Postoperative Nefopam and Diclofenac. Evaluation of Their Morphine-Sparing Effect After Upper Abdominal Surgery, <i>Anaesthesia</i> (1990), United Kingdom, vol. 45, no. 4, pages 302-305.	
/S.J./	R6	PILLANS P.I. <i>et al.</i> , Adverse Reactions Associated With Nefopam, <i>The New Zealand Medical Journal</i> (Sept. 22, 1995), New Zealand, vol. 108, no. 1008, pages 382-384.	

Examiner Signature	/Sahar Javanmard/	Date Considered	06/28/2007
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.